RECENTLY ACTIVATED: EAZ171 TRIAL FOR PERIPHERAL NEUROPATHY IN AFRICAN AMERICAN WOMEN WITH BREAST CANCER

Recent research shows patients of African ancestry have a much higher risk of experiencing side effects from chemotherapy, especially neuropathy, and thus have a higher risk of discontinuing treatment. This results in increased recurrence and worse survival rates in Black patients compared with White patients. EAZ171, led by Bryan P. Schneider, MD (Indiana University, pictured right), aims to improve outcomes for Black women with breast cancer by:

1. Determining which women are most at risk for neuropathy based on their DNA, and
2. Determining which regularly prescribed chemotherapy treatment, docetaxel or paclitaxel, will result in less neuropathy

Through this work, researchers hope to definitively conclude which treatment is better, and less likely to cause neuropathy, for women of African ancestry. They also hope to learn more about why Black women, specifically, are more susceptible to neuropathy. Learn more.